Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
VALENCIA, Calif., Jan. 09, 2017 -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today confirmed that it received $30.6 million from Sanofi on January 6, 2017, representing the balance of the accelerated insulin “put” option previously exercised by MannKind. This payment was made pursuant to a previously disclosed agreement reached with Sanofi on November 9, 2016.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya SVP, Finance 661-775-5300 [email protected]
